Mucibrón (Ambroxol Hydrochloride)

Ambroxol stimulates serous cells in the airway lining, increasing the secretion of thin, watery fluid. It also enhances the activity of cilia and reduces the viscosity of mucus by breaking down its glycoprotein structure. These actions together promote more efficient mucociliary clearance, helping patients expel mucus more easily.

The appropriate dose of Mucibrón is determined by a qualified healthcare professional based on the patient’s age, weight, severity of symptoms, and overall clinical condition. Prescribers follow local guidelines and product labeling to select the correct strength and frequency for each individual case.

Safety data for Ambroxol in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should evaluate the potential benefits against possible risks before prescribing Mucibrón to pregnant or nursing mothers.

To request Mucibrón, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Both Ambroxol (Mucibrón) and guaifenesin act as expectorants, but Ambroxol is a mucolytic that actively reduces mucus viscosity and stimulates serous secretion, whereas guaifenesin primarily increases airway fluid volume. Ambroxol may provide faster relief in conditions with thick, tenacious sputum, while guaifenesin is often used for milder congestion.

Mucibrón should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme heat. Keep it out of reach of children and do not use it after the expiry date indicated on the label.

Mucibrón is taken orally, usually with a glass of water. The tablet or liquid should be swallowed whole unless the prescribing information advises otherwise. Patients are encouraged to follow the dosing schedule prescribed by their healthcare professional and to maintain adequate hydration to support mucus clearance.

Although rare, serious adverse reactions can include allergic responses such as urticaria, angioedema, severe skin reactions (e.g., Stevens‑Johnson syndrome), hepatic enzyme elevation, eosinophilia, and anaphylaxis. Any signs of swelling, rash, difficulty breathing, or unusual liver-related symptoms should prompt immediate medical attention.

Mucibrón should be avoided in individuals with known hypersensitivity to Ambroxol or any excipients in the formulation. Patients with severe renal impairment should use it only under medical supervision, and those with active peptic ulcer disease should be cautious due to potential gastric irritation. Pregnant or breastfeeding women should consult their physician before use.